Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Cytomegalovirus Infections Clinical Trials

A listing of Cytomegalovirus Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Third-Party Cytotoxic T-Lymphocytes (CTLs) for Cytomegalovirus (CMV) Infection

The CTLs: CTLs are made at MD Anderson from healthy donor blood cells. The healthy donors were donating blood stem cells for other stem cell transplant patients. The cells are from a donor who at least partially matches you and your donor. All donors have been screened in the same ...

Phase

Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)

To make CMV-specific T cells (Viralym-C cells), small pieces of protein called peptides that come from CMV were mixed with blood cells from healthy donors. These peptides train a kind of white blood cell called T cells to recognize and kill cells that are infected with CMV. These T cells ...

Phase

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after kidney transplantation. Therefore most of the patients receive an universal prophylaxis. On the contrary to CMV naïve patients, seropositive recipients (R+) have already mounted a specific immunologic response directed against the virus, which is not completely abrogated by immunosuppressive ...

Phase

Study to Evaluate Safety Tolerability and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

This study is designed to assess safety and immunogenicity of four dose formulations of cytomegalovirus (CMV) vaccine (0.5 μg gB content with aluminum phosphate (alum), 1.0 μg glycoprotein B (gB) content with alum, 2.0 μg gB content with alum, or 1.0 μg gB content (without alum) as compared with placebo ...

Phase